TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Blinklab Limited ( (AU:BB1) ).
BlinkLab Limited has announced that Rush University Medical Center has joined its pivotal U.S. clinical study for the BlinkLab Dx 1 autism diagnostic aid, expanding its network to eight leading autism centers. This development follows a successful U.S. Pilot Study, where BlinkLab Dx 1 demonstrated high sensitivity and specificity, exceeding FDA benchmarks. The pivotal study will enroll 528 children and aims to support U.S. market access planning for the AI-powered diagnostic solution, positioning BlinkLab for breakthrough commercialization.
More about Blinklab Limited
BlinkLab Limited is a leader in AI-powered digital diagnostics, focusing on developing scalable diagnostic solutions. The company is engaged in creating a smartphone-based autism diagnostic aid, BlinkLab Dx 1, and is actively involved in clinical studies to enhance its market presence.
Average Trading Volume: 304,252
Technical Sentiment Signal: Buy
Current Market Cap: A$99.16M
See more insights into BB1 stock on TipRanks’ Stock Analysis page.